-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2015 Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India

Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I
Hematology Disease Topics & Pathways:
Research, Biological therapies, adult, clinical trials, Translational Research, Lymphomas, non-Hodgkin lymphoma, assays, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Clinical Research, Diseases, cell expansion, Therapies, Immunotherapy, Lymphoid Malignancies, Adverse Events, emerging technologies, Technology and Procedures, gene editing, Study Population, Human, molecular testing
Saturday, December 10, 2022, 5:30 PM-7:30 PM

Atharva Karulkar, PhD1,2*, Hasmukh Jain, MD, DM3*, Shreshtha Shah1*, Aalia Khan2*, Ankesh Jaiswal2*, Afrin Firfiray1,2*, Prashant Suvasia2*, Priyanshi Suvasia2*, Juber Pendhari2*, Sweety Asija2*, Ambalika Chowdury2*, Ankit Banik2*, Smrithi Ravikumar1*, Neha Sharma4*, Minal Poojary, MD5*, Sumathi Hiregoudar, MD6*, Preeti Desai, MD7*, Anisha Navkudkar, MD7*, Sunil Rajadhyaksha7*, Jayashree Thorat, MD, DM8*, Prashant R. Tembhare, MD9, Albeena Nisar, PhD10*, Manju Sengar, MD, DM 11, David F. Stroncek, MD12, Steven Highfill, PhD12*, Nirali N. Shah, MD13, Gaurav Narula, MD14* and Rahul Purwar, PhD1,2*

1Immunoadoptive Cell Therapy Pvt Ltd (ImmunoACT), Navi Mumbai, India
2Indian Institute of Technology Bombay, Mumbai, India
3Department of Medical Oncology, Tata Memorial Centre, Mumbai, India
4Department of Medical Oncology, Tata Memorial Centre, Affiliated to Homi Bhabha National Institute, Mumbai, India
5Tata Memorial Centre Affiliated to Homi Bhabha National Institute, Kharghar, India
6Department of Transfusion Medicine, ACTREC, Sector 22, Navi Mumbai, Tata Memorial Centre, Affiliated to Homi Bhabha National Institute, Navi Mumbai, India
7Department of Transfusion Medicine, Tata Memorial Centre, Affiliated to Homi Bhabha National Institute, Mumbai, India
8Department of Medical Oncology, Tata Memorial Centre, Affiliated to Homi Bhabha National Institute, Mumbai, Maharashtra, India
9Hematopathology Lab, Tata Memorial Centre, Affiliated to Homi Bhabha National Institute, Mumbai, India
10Tata Memorial Centre, Affiliated to Homi Bhabha National Institute, Mumbai, AL, India
11Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India
12Center for Cellular Engineering, National Institutes of Health, Bethesda, MD
13Pediatric Oncology Branch, National Institutes of Health, Bethesda, MD
14Department of Pediatric Oncology, Tata Memorial Center, Affiliated to Homi Bhabha National Institute, Mumbai, India

Background: Chimeric Antigen Receptor (CAR) T cells therapy has shown remarkable success in haematological malignancies. However, complexity of the manufacturing platform and exorbitant costs of the available therapy limits their accessibility in limited resource settings including India. Recently, we developed a novel humanized anti-CD19 CAR-T cell therapy (HCAR19) and showed its efficacy in preclinical models (Dwivedi et al, Mol Cancer Ther. 2021). Here we report our experience of HCAR19 manufacturing in an integrated platform for first-in-human Phase-I clinical trial. Further, we performed the cost analysis of CAR-T delivery from development to clinic.

Methods:

Lymphocytes were collected from 17 patients of r/r B cell malignancies (DLBCL, transformed follicular lymphoma, PMBCL and B-ALL) through apheresis (Fresenius Fomtek or Spectra Optia) upon receiving the regulatory approvals from central and local agencies. CD3+ T cells were enriched and activated using CTS™Dynabeads™ CD3/CD28 for 36-48 hours followed by consecutive double transduction with CD19 encoding lentivirus vector. Final product was harvested, cryopreserved and stored in ultra-low temperature until further use. All steps were carried out in closed gas permeable bags. Final product quality control (QC) assays were performed by flowcytometry, ELISA, analytical and cell-based assays. The cost of CAR T cell manufacturing was calculated for unit economics on fully scale production model by standard costing methodology. The final unit economics included cost of goods and services (COGS), overhead costs, financing costs of infrastructure, R&D and clinical trials costs. The model was scaled towards a 200 patient per annum in a centralized manufacturing facility.

Results:

Of the 19 patients enrolled in the study, only 17 patients underwent apheresis procedure for harvest of total 5-10 X 109 mononuclear cells. HCAR19 cells from all 17 patients were manufactured successfully in functionally closed integrated manufacturing platform. The required HCAR19 dose was achieved within 8 days of culture (dosage range: 1.78 x 106 - 17 x 106 viable HCAR19/kg). The transduction efficiency of HCAR19 in r/r DLBCL, r/r PMBCL and r/r B-ALL was 37.7 ± 6.64%, 28.8 ± 8.81% and 34.6 ± 9.72% (Mean ± SEM) respectively . The HCAR19 showed a robust expansion (~20-fold) ex vivo and maintained the presence of potent anti-tumor subsets like naïve and central memory T cells (Figure 1a). Final product from all 17 patients qualified the QC release criteria for safety, identity, purity and potency as per specifications. Finally, the unit economics in fully-scaled production model indicated the estimated cost of CAR-T cell delivery was approximately 30,000 USD (or 25,00,000 INR) per dosage including logistics, lentiviral vector cost and quality control (Figure 1b). The major costs incurred were towards consumables, overhead and financing costs of clinical trials and infrastructure. There was very minor components of logistics and utility costs. More importantly, the major contributors of overall low cost of CAR-T delivery in our settings were frugal R&D costs in an academic setting, scalable integrated manufacturing platform, and highly qualified yet economical manpower.

Conclusions:

We developed a robust, scalable and highly affordable CAR-T cell therapy platform (product and process development, and first-in-human clinical study), and proven its clinical delivery successfully with our first indigenous HCAR19 product. Given the benefit of affordable platform to broader socio-economic base of patients, the cell and gene therapy will be poised for a transformational change as a mass therapy.

Disclosures: Karulkar: Immunoadoptive Cell Therapy Pvt Ltd: Current Employment. Shah: ImmunoAdaptive Therapy Pvt Ltd: Current Employment. Firfiray: Immunoadoptive Cell Therapy Pvt Ltd: Current Employment. Ravikumar: ImmunoAdoptive Therapy Pvt Ltd: Current Employment. Purwar: Immunoadoptive Cell Therapy Pvt Ltd: Current Employment, Current equity holder in private company.

*signifies non-member of ASH